BTD rs397507173: Understanding Carrier Status
The rs397507173 variant is a rare genetic change located within the BTD gene. It is recognized as a carrier variant, meaning individuals who carry this change may have a predisposition to pass on autosomal recessive biotinidase deficiency to their offspring.
What each genotype means
Typical BTD gene profile
This genotype represents the common, non-variant form of the BTD gene at this location. Individuals with this profile are not considered carriers of this specific pathogenic variant associated with biotinidase deficiency.
This is the most common genotype found in the general population.
Carrier of biotinidase deficiency
This genotype indicates you carry one copy of a pathogenic variant in the BTD gene. As biotinidase deficiency is an autosomal recessive condition, carrying a single copy typically does not cause symptoms, but you may pass this variant to your children.
This specific variant is very rare, with a minor allele frequency of less than 0.001 in global populations.
Increased risk for deficiency
This genotype indicates the presence of two copies of the pathogenic variant, which is associated with biotinidase deficiency. You should discuss these results with a healthcare provider or a genetic counselor to understand the clinical implications and potential for enzyme activity reduction.
This genotype is extremely rare in the general population.
What is rs397507173?
The rs397507173 variant is a specific single nucleotide polymorphism (SNP) located on chromosome 3 within the BTD gene. In genetic databases, this variant is often identified by its position and the specific change in the DNA sequence, where a cytosine (C) is replaced by a thymine (T). Because it is a rare variant, it is not typically found in the general population at high frequencies. Geneticists track such variants to understand how they might influence biological processes or contribute to inherited conditions. When a variant is identified as a carrier marker, it indicates that the change is associated with a recessive trait, which generally requires two copies of the variant—one inherited from each parent—to potentially manifest the associated clinical condition. Understanding the location and nature of this SNP is the first step in interpreting its role in human health.
The Role of the BTD Gene
The BTD gene provides the essential instructions for the body to produce an enzyme called biotinidase. This enzyme plays a critical role in recycling biotin, a B vitamin that is vital for various metabolic processes, including the breakdown of fats, proteins, and carbohydrates. By cleaving biocytin, a byproduct of protein degradation, biotinidase regenerates free biotin so the body can reuse it. When the BTD gene contains pathogenic variants, the production or function of this enzyme can be impaired. This impairment leads to biotinidase deficiency, a condition that can be classified as either profound or partial depending on the level of residual enzyme activity. Because biotin is necessary for many cellular functions, a deficiency can lead to a range of neurological and metabolic symptoms if not managed appropriately, often through biotin supplementation.
Research and Evidence Strength
The evidence linking rs397507173 to biotinidase deficiency is categorized as limited. While clinical databases like ClinVar have documented this variant in the context of biotinidase deficiency, the overall body of research is still evolving. It is important to note that biotinidase deficiency follows an autosomal recessive inheritance pattern. This means that being a carrier—having only one copy of a pathogenic variant—typically does not result in the clinical symptoms of the deficiency. The primary clinical relevance of identifying this variant is for carrier screening, which helps individuals understand the likelihood of passing the variant to their children. Because the evidence is limited, researchers continue to study how this specific variant impacts enzyme activity levels. As with all genetic findings, the clinical significance of a variant can be complex and may depend on other genetic factors or the specific context of an individual's health history.
Population Frequency
The rs397507173 variant is considered very rare on a global scale. According to data from large-scale genomic projects like gnomAD, the minor allele frequency for this variant is typically reported as less than 0.001. This low frequency indicates that the variant is not widespread in the general population and is found only in a very small fraction of individuals. Because it is so rare, it is not a common finding in routine genetic testing. The rarity of the variant underscores the importance of specialized testing if there is a known family history of biotinidase deficiency or if a clinical concern has been raised by a healthcare provider. Genomic databases continue to update their frequency data as more individuals from diverse ancestral backgrounds are sequenced, providing a clearer picture of how rare this variant truly is across different global populations.
Interpreting Your Results
If you have received information regarding your status for rs397507173, it is essential to understand what this means in a practical sense. This information is intended for educational purposes and should not be used as a medical diagnosis. If you are concerned about your carrier status or the potential for passing a genetic condition to your children, the most appropriate step is to consult with a qualified healthcare professional, such as a genetic counselor or a medical geneticist. They can provide context based on your personal and family health history, explain the implications of being a carrier, and discuss whether further diagnostic testing is necessary. Never make changes to your health management or medication based solely on a genetic report without professional guidance. A clinician can help you navigate the complexities of genetic data and ensure that any decisions you make are informed by accurate, personalized medical advice.
How common is this variant?
The rs397507173 variant is very rare globally, with a minor allele frequency of less than 0.001 in major population databases like gnomAD.
Frequently asked questions
What is biotinidase deficiency?
Biotinidase deficiency is an inherited metabolic disorder where the body cannot recycle the vitamin biotin. If left untreated, it can lead to neurological and skin-related symptoms, but it is often manageable with biotin supplementation.
Does being a carrier for rs397507173 mean I am sick?
No, being a carrier for an autosomal recessive condition like biotinidase deficiency typically means you do not have the condition yourself. Carriers have one copy of the variant and one normal copy of the gene, which is usually sufficient for normal enzyme function.
Should I be tested for this variant?
Genetic testing is usually recommended if you have a family history of biotinidase deficiency or if you are planning a family and want to understand your carrier status. You should discuss the necessity of testing with a genetic counselor or your primary care physician.
Is there a cure for biotinidase deficiency?
While there is no 'cure' in the sense of fixing the gene, biotinidase deficiency is highly treatable. Individuals with the condition take daily biotin supplements to compensate for the enzyme deficiency, which can prevent or reverse most symptoms.
Sources & further reading
Educational information only, last refreshed 9/22/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs397507173?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in BTD
Carrier variant associated with autosomal recessive biotinidase deficiency.
Pathogenic variant in the BTD gene associated with biotinidase deficiency, an autosomal recessive metabolic disorder.
This variant is linked to biotinidase deficiency, where heterozygous carriers may be identified through clinical screening.
This variant is identified as a carrier mutation for biotinidase deficiency.
This variant is a known carrier mutation for biotinidase deficiency.
This variant is associated with carrier status for biotinidase deficiency.